Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 11, 2006, Pages 1461-1466

  Van Der Graaf, Anouk ^a   Nierman, Melchior C ^a   Firth, Jean C ^b   Wolmarans, Karen H ^b   Marais, A David ^b   De Groot, Eric ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Atherosclerosis; Familial hypercholesterolaemia; Prevention

Indexed keywords

FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ARTERY WALL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HETEROZYGOSITY; HORMONE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; INTIMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCHOOL CHILD; SEXUAL MATURATION;

ADOLESCENT; ATHEROSCLEROSIS; CAROTID ARTERIES; CHILD; DELAYED-ACTION PREPARATIONS; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; INDOLES; LIPIDS; MALE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 33750408454     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250600702602     Document Type: Article

References (21)

1. Vuorio AF, Kovanen PT, Gylling H. Hypolipidemic treatment of heterozygous familial hypercholesterolemia: a lifelong challenge. Expert Rev Cardiovasc Ther 2004;2:405-15.
2. Hopkins PN. Familial hypercholesterolemia - improving treatment and meeting guidelines. Int J Cardiol 2003;89:13-23.
3. Slack J. Risk of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969;2:1380-2.
4. Virkola K, Pesonen E, Akerblom HK, Siimes MA. Cholesterol and carotid artery wall in children and adolescents with familial hypercholesterolaemia: a controlled study by ultrasound. Acta Paediatr 1997;86:1203-7.
5. Wiegman A, Rodenburg J, de Jongh S, Defesche JC, Bakker HD, Kastelein JJ, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003;107:1473-8.
6. Holmes DT, Schick BA, Humphries KH, Frohlick J. Lipoprotein (a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005;5:2067-73.
7. Tonstad S, Thompson GR. Management of hyperlipidemia in the pediatric population. Curr Treat Options Cardiovasc Med 2004;6:431-7.
8. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia. JAMA 1999;281:137-44.
9. de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, et al. for the Simvastatin in Children Study Group. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. A randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002;106:2231-7.
10. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005;116:682-8.
11. Hedman M, Matikainen T, Föhr A, Lappi A, Piippo S, Nuutinen M, et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metabl 2005;90:1942-52.
12. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia. JAMA 2004;292: 331-7.
13. de Jongh S, Lilien MR, op't Roodt J, Stroes ESG, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002;40:2117-21.
14. Nolting PR, de Groot E, Zwinderman AH, Buirma RJ, Trip MD, Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 2003;163:1837-41.
15. Zavoral JH, Haggerty BJ, Winick AG, Bergmann SD. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial. Am J Cardiol 1995; 76:37A-40A.
16. Banga JD, Jacotot B, Pfister P, Mehra M. Long-term treatment of hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy study. French-Dutch Fluvastatin Study Group. Am J Med 1994;96:87S-93S.
17. Ballantyne CM, Pazzucconi F, Pinto X, Reckless JP, Stein E, McKenney J, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001;23:177-92.
18. De Groot E, Zwinderman AH, van der Steen AF, Ackerstaff RG, Montauben van Swijndregt AD, Bom N, et al. REGRESS Study Group, Interuniversity Cardiology Institute of The Netherlands, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. Variance components analysis of carotid and femoral intima-media thickness measurements. Ultrasound Med Biol 1998;24:825-32.
19. De Groot E, Jukema W, Montauban van Swijndregt AD, Zwinderman AH, Ackerstaff RG, van der Steen AF, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary angiographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998;31:1561-7.
20. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol 2002;22:1175-80.
21. Tonstad S, Joakimsen O, Stensland-Bugge E, Leren TP, Ose L, Russell D, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996;16:984-91.